Infinity Pharmaceuticals diagnostics interface makes it easy to digest most current publicly released information about Infinity Pharmaceuticals as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Infinity Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.
About 54.0% of the company shares are owned by institutional investors. The book value of Infinity Pharmaceuticals was currently reported as 0.94. The company recorded loss per share of 0.83. Infinity Pharmaceuticals had not issued any dividends in recent years. This company had 1:4 split on 2006-09-13. Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 22 people. To learn more about INFINITY PHARMACE call Adelene Perkins at 617-453-1000 or check out http://www.infi.com.
Infinity Pharmaceuticals Alerts
Infinity Pharmaceuticals appears to be very risky and stock price may revert if volatility continues
Infinity Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported previous year revenue of 6 M. Net Loss for the year was (41.83 M) with profit before overhead, payroll, taxes, and interest of 6 M.
INFINITY PHARMACE currently holds about 57.61 M in cash with (36.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.11.
Financial Statements and Exhibits. Results of Operations and Financial Condition
The company currently falls under 'Small-Cap' category with current market capitalization of 115.87 M.
Infinity Pharmaceuticals has return on total asset (ROA) of (24.62) % which means that it has lost $24.62 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (64.26) % meaning that it created substantial loss on money invested by shareholders.
The output start index for this execution was eleven with a total number of output elements of twenty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Infinity Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Infinity Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.